Therefore one can suggest that the tumour derived PlGF in our breast cancer patients suppresses tumour angiogenesis, tumour growth and metastasis by a probable mechanism including PlGF homodimers or PlGF–VEGF heterodimers, activating a negative neovascularisation feedback via sFlt1 activation. Here, PGF is linked to breast carcinoma.